XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.20.2

Stock Options | 3 Months Ended
--- | ---
Sep. 30, 2020
Stock Options |
Stock Options | NOTE 8 - Stock Options The Company follows ASC Topic 718, "Compensation-Stock Compensation", which requires that all share based payments to employees, including stock options, be recognized as compensation expense in the consolidated financial statements based on their fair values and over the requisite service period. The Company recorded non-cash compensation expense relating to stock-based compensation of $104,000 and $17,000 for the three months ended September 30, 2020 and 2019, respectively ($0.01 and $0.00 per basic and diluted share for each period, respectively). 2012 Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Employee Stock Option Plan (" 2012 Employee Plan"). The 2012 Employee Plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 950,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options, which are intended to qualify as incentive stock options ("ISOs"), to valued employees. Any plan participant who is granted ISOs and possesses more than 10% of the voting rights of the Company’s outstanding common stock must be granted an option with a price of at least 110% of the fair market value on the date of grant. Under the 2012 Employee Plan, stock options may be granted to valued employees with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable, in whole or in part, at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At September 30, 2020, 117,840 stock options were outstanding, 37,400 stock options were exercisable and 731,960 stock options were available for grant under this plan. No options were granted during the three months ended September 30, 2020. The fair value of each option granted during the three months ended September 30, 2019 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​
​ | ​ | 2019 |
Risk-free interest rates | ​ | 2.10 | %
Expected lives | ​ | 10 years | ​
Expected volatility | ​ | 46 | %
Expected dividend yields | ​ | 0 | %
​ The following table reflects activity under the 2012 Employee Plan for the three months ended September 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2020 | ​ | ​ | 2019
​ | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average
​ | ​ | Options |  | exercise price |  | Options |  | exercise price
Outstanding, beginning of year | ​ | ​ | 117,840 | ​ | $ | 18.84 | ​ | ​ | 72,500 | ​ | $ | 11.01
Granted | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8,000 | ​ | ​ | 26.06
Exercised | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | —
Outstanding, end of period | ​ | ​ | 117,840 | ​ | $ | 18.84 | ​ |  | 80,500 | ​ | $ | 12.51
Exercisable, end of period | ​ | ​ | 37,400 | ​ | $ | 13.73 | ​ |  | 35,400 | ​ | $ | 8.62
Weighted average fair value at grant date of options granted | ​ | ​ | n/a | ​ |  | ​ | ​ | $ | 15.17 | ​ |  | ​
Total intrinsic value of options exercised | ​ | ​ | n/a | ​ | ​ | ​ | ​ | ​ | n/a | ​ |  | ​
Total intrinsic value of options outstanding | ​ | $ | 706,000 | ​ | ​ | ​ | ​ | $ | 1,052,000 | ​ |  | ​
Total intrinsic value of options exercisable | ​ | $ | 399,000 | ​ | ​ | ​ | ​ | $ | 599,000 | ​ |  | ​
​ No stock options were exercised during the three months ended September 30, 2020 or 2019. Accordingly, the actual tax benefit realized for the tax deductions from option exercises was $0 for both periods. ​ The following table summarizes information about stock options outstanding under the 2012 Employee Plan at September 30, 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | ​ | ​ |  | ​ |  | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | exercise price | ​ | exercisable | ​ | exercise price
$4.37‑$33.59 | ​ | 117,840 | ​ | 8.1 | ​ | $ | 18.84 | ​ | 37,400 | ​ | $ | 13.73
​ | ​ | 117,840 | ​ | 8.1 | ​ | $ | 18.84 | ​ | 37,400 | ​ | $ | 13.73
​ As of September 30, 2020, there was $792,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Employee Plan. 0 and 8,000 options were granted during the three months ended September 30, 2020 and 2019, respectively. 2,400 and 1,600 options vested during the three months ended September 30, 2020 and 2019, respectively. The total fair value of the options vesting during the three months ended September 30, 2020 and 2019 under this plan was $29,000 and $17,000 respectively. 2012 Non-Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Non-Employee Stock Option Plan (the “2012 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 50,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2012 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At September 30, 2020, 12,000 stock options were outstanding, 5,760 stock options were exercisable and no further stock options were available for grant under this plan. The following table reflects activity under the 2012 Non-Employee Plan for the three months ended September 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2020 | ​ | ​ | 2019
​ | ​ | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average
​ | ​ | Options | ​ | exercise price | ​ | Options | ​ | exercise price
Outstanding, beginning of year | ​ | ​ | 12,000 | ​ | $ | 10.29 | ​ | ​ | 10,200 | ​ | $ | 7.99
Granted | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Exercised | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | —
Outstanding, end of period | ​ | ​ | 12,000 | ​ | $ | 10.29 | ​ |  | — | ​ | ​ | —
Exercisable, end of period | ​ | ​ | 5,760 | ​ | $ | 8.35 | ​ |  | 10,200 | ​ | $ | 7.99
Weighted average fair value at grant date of options granted | ​ | ​ | n/a | ​ | ​ | ​ | ​ | ​ | n/a | ​ |  |
Total intrinsic value of options exercised | ​ | ​ | n/a | ​ | ​ | ​ | ​ | ​ | n/a | ​ |  |
Total intrinsic value of options outstanding | ​ | $ | 159,000 | ​ | ​ | ​ | ​ | $ | 179,000 | ​ |  |
Total intrinsic value of options exercisable | ​ | $ | 87,000 | ​ | ​ | ​ | ​ | $ | 58,000 | ​ |  |
​ No stock options were exercised during the three months ended September 30, 2020 or 2019. No cash was received from option exercises during either of the three months ended September 30, 2020 or 2019 and the actual tax benefit realized for the tax deductions from option exercises was $0 for both periods. The following table summarizes information about stock options outstanding under the 2012 Non-Employee Plan at September 30, 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | Weighted |  | ​ |  | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding |  | contractual life | ​ | price | ​ | exercisable | ​ | price
$4.37 - $23.35 | ​ | 12,000 | ​ | 7.0 | ​ | $ | 10.29 | ​ | 5,760 | ​ | $ | 8.35
​ | ​ | 12,000 | ​ | 7.0 | ​ | $ | 10.29 | ​ | 5,760 | ​ | $ | 8.35
​ As of September 30, 2020, there was $28,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Non-Employee Plan. No options were granted during the three months ended September 30, 2020 or 2019. No options vested during the three months ended September 30, 2020 and 2019, respectively. 2018 Non-Employee Stock Option Plan In December 2018, the stockholders approved the 2018 Non-Employee Stock Option Plan (the “2018 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 50,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2018 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At September 30, 2020, 48,400 stock options were outstanding, 12,240 stock options were exercisable and 0 stock options were available for grant under this plan. The following table reflects activity under the 2018 Non-Employee Plan for the three months ended September 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2020 | ​ | ​ | 2019
​ |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average
​ | ​ | Options |  | exercise price | ​ | ​ | Options |  | exercise price
Outstanding, beginning of year | ​ | ​ | 48,400 | ​ | $ | 23.48 | ​ | ​ | 15,200 | ​ | $ | 16.20
Granted | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | —
Exercised | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | —
Outstanding, end of period | ​ | ​ | 48,400 | ​ | $ | 23.48 | ​ |  | 15,200 | ​ | $ | 16.20
Exercisable, end of period | ​ | ​ | 12,240 | ​ | $ | 21.96 | ​ |  | 2,400 | ​ | $ | 16.20
Weighted average fair value at grant date of options granted | ​ | ​ | n/a | ​ | ​ | ​ | ​ | ​ | n/a | ​ | ​ | ​
Total intrinsic value of options exercised | ​ |  | n/a | ​ | ​ | ​ | ​ | ​ | n/a | ​ | ​ | ​
Total intrinsic value of options outstanding | ​ | $ | 114,000 | ​ | ​ | ​ | ​ | $ | 142,000 | ​ | ​ | ​
Total intrinsic value of options exercisable | ​ | $ | 41,000 | ​ | ​ | ​ | ​ | $ | 22,000 | ​ | ​ | ​
​ No stock options were exercised during the three months ended September 30, 2020 or 2019. No cash was received from option exercises during either of the three ended September 30, 2020 or 2019 and the actual tax benefit realized for the tax deductions from option exercises was $0 for each of these periods. The following table summarizes information about stock options outstanding under the 2018 Non-Employee Plan at September 30, 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | Weighted |  | ​ |  | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | price | ​ | exercisable | ​ | price
$16.20-$30.54 | ​ | 48,400 |  | 8.9 | ​ | $ | 23.48 |  | 12,240 | ​ | $ | 21.96
​ | ​ | 48,400 |  | 8.9 | ​ | $ | 23.48 |  | 12,240 | ​ | $ | 21.96
​ As of September 30, 2020, there was $377,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2018 Non-Employee Plan. 0 options were granted during the three months ended September 30, 2020 and 2019, respectively. No options vested during either of the three months ended September 30, 2020 or 2019. ​ 2020 Non-Employee Stock Option Plan In May 2020, the stockholders approved the 2020 Non-Employee Stock Option Plan (the “2020 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 50,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2020 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At September 30, 2020, 5,000 stock options were outstanding, 1,000 stock options were exercisable and 45,000 stock options were available for grant under this plan. The fair value of each option granted during the three months ended September 30 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​
​ |  | 2020 |
Risk-free interest rates |  | 0.62 | %
Expected lives |  | 10 years | ​
Expected volatility |  | 45 | %
Expected dividend yields |  | 0 | %
​ The following table reflects activity under the 2020 Employee Plan for the three months ended September 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2020
​ | ​ | ​ | ​ | ​ | Weighted average
​ |  | Options |  | exercise price
Outstanding, beginning of year |  | ​ | — |  | ​ | —
Granted |  | ​ | 5,000 | ​ | $ | 22.80
Exercised |  | ​ | — | ​ |  | —
Outstanding, end of period |  | ​ | 5,000 | ​ | $ | 22.80
Exercisable, end of period |  | ​ | 1,000 | ​ | $ | 22.80
Weighted average fair value at grant date of options granted | ​ | $ | 12.20 | ​ |  |
Total intrinsic value of options exercised | ​ |  | n/a | ​ |  |
Total intrinsic value of options outstanding | ​ | $ | 4,000 | ​ |  |
Total intrinsic value of options exercisable | ​ | $ | 1,000 | ​ |  |
​ No stock options were exercised during the three months ended September 30, 2020 or 2019. Accordingly, the actual tax benefit realized for the tax deductions from option exercises was $0 for both periods. The following table summarizes information about stock options outstanding under the 2012 Employee Plan at September 30, 2020:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices |  | outstanding |  | contractual life |  | exercise price | ​ |  | exercisable |  | exercise price | ​
$22.80 |  | 5,000 |  | 9.9 | ​ | $ | 22.80 |  | 1,000 | ​ | $ | 22.80
​ |  | 5,000 |  | 9.9 | ​ | $ | 22.80 |  | 1,000 | ​ | $ | 22.80
​ As of September 30, 2020, there was $46,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2020 Employee Plan. 5,000 options were granted during the three months ended September 30, 2020. 1,000 options vested during the three months ended September 30, 2020. The total fair value of the options vesting during the three months ended September 30, 2020 under this plan was $12,000.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration